AI Article Synopsis
- The management of advanced breast cancer is increasingly complex due to new treatment innovations, necessitating comprehensive approaches in patient care.
- Biopsies of metastatic sites are crucial at the diagnosis of metastatic disease to refine treatment options, as many patients may lose hormone receptor expression upon recurrence.
- Clinical data from the ASCENT trial highlights the benefits of sacituzumab govitecan for non-triple negative breast cancer that later converts to triple negative, illustrating evolving treatment strategies.
Article Abstract
The management of patients with advanced breast cancer is becoming increasingly complex compared to the past, mainly due to numerous therapeutic innovations introduced in the current therapeutic scenario. At the time of metastatic disease diagnosis, as indicated by the guidelines, it is important to perform a biopsy of the metastatic sites to optimize choices and expand therapeutic options. Approximately 25-45% of patients who experience a recurrence of the primary tumor lose hormone receptor expression: in this context, solid data comes from a subanalysis of the randomized clinical trial ASCENT, in which the benefit of a treatment with antibody-drug conjugate sacituzumab govitecan is also confirmed in case of non-triple negative breast cancer at diagnosis that subsequently convert to a triple negative subtype. The case reported below is representative of this clinical situation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1701/4357.43481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!